knowledge -WSS

knowledge

author：fashion 2025-09-14 14:40:34 - browse：76677

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Today's health inequities arise from racist U.S. history, say experts

entertainment

WSS

Carbon Health diabetes program, a test of data

First Opinion Podcast: How to protect health care in times of war

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Traditional Chinese medicine benefits explored in new JAMA study

Eli Lilly to pay $200M for Beam’s stake in gene

entertainment

knowledge

Wikipedia

Psychedelics group wrestles with new pharma identity

CVS, Rite Aid closures threaten to worsen pharmacy deserts

At least 13 dead in Texas as scorching temps continue

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Anesthesiologist group: stop taking Ozempic before surgery

Maker of FluMist seeks to allow at

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Trump demands the U.S. pay no more for drugs than other countries … again

Medical school prerequisites are outdated

knowledge

UnitedHealth sued over use of algorithm in Medicare Advantage plans

A letter from the executive editor: STAT UnitedHealth investigation

NIH chief: government has fallen behind pharma on clinical trials

Weight loss drugs should be covered by insurers, AMA says

What is STAT's opinion section for?

First Opinion Podcast: How to protect health care in times of war

focus

focus

entertainment

focus